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Abstract
The contribution of microRNAs (miR) to the pathogenesis of
mantle cell lymphoma (MCL) is notwell known.We investigated
the expression of 86 maturemiRs mapped to frequently altered
genomic regions in MCL in CD5+/CD5 normal B cells, reactive
lymph nodes, and purified tumor cells of 17 leukemic MCL, 12
nodal MCL, and 8 MCL cell lines. Genomic alterations of the
tumors were studied by single nucleotide polymorphism arrays
and comparative genomic hybridization. Leukemic and nodal
tumors showed a high number of differentially expressed miRs
compared with purified normal B cells, but only some of them
were commonly deregulated in both tumor types. An unsuper-
vised analysis of miR expression profile in purified leukemic
MCL cells revealed two clusters of tumors characterized by
different mutational status of the immunoglobulin genes,
proliferation signature, and number of genomic alterations.
The expression of most miRs was not related to copy number
changes in their respective chromosomal loci. Only the levels
of miRs included in the miR-17-92 cluster were significantly
related to genetic alterations at 13q31. Moreover, overexpres-
sion of miR-17-5p/miR-20a from this cluster was associated
with high MYC mRNA levels in tumors with a more aggressive
behavior. In conclusion, the miR expression pattern of MCL is
deregulated in comparison with normal lymphoid cells and
distinguishes two subgroups of tumors with different biological
features. [Cancer Res 2009;69(17):7071–8]
Introduction
MicroRNAs (miR) are noncoding regulatory small RNAs gen-
erated from larger precursors with a hairpin-like structure (1, 2).
These small RNAs bind to specific mRNA transcripts leading to
their degradation and/or translational blocking (3, 4). Different
studies have shown their contribution to the modulation of cellular
processes such as differentiation, proliferation, and apoptosis that
play an important role in oncogenesis (5, 6). miRs are located
throughout the genome and are often found in chromosomal loci
altered in different neoplasms (7). Genomic alterations including
gains/amplifications, losses, and translocations of these regions
could be a causal event of miR deregulation in cancer (8, 9).
Mantle cell lymphoma (MCL) is genetically characterized by
the t(11;14)(q13;q32) translocation resulting in rearrangement and
overexpression of the CCND1 gene (10). In addition to this primary
genetic alteration, most MCL carry a high number of recurrent
secondary gains and losses as well as uniparental disomies, homo-
zygous deletions, and high-level DNA amplifications (11, 12). In a
recent review of the potential genes that could be targeted by
recurrent MCL chromosomal aberrations, we noticed the presence
of a relatively high number ofmiRs in these regions (13). Interestingly,
some of the miRs involved have been shown to modulate genes
related to the regulation of cell cycle and survival pathways, two
mechanisms that have an important role in the progression of MCL
(14). However, the miR expression profile in MCL and their potential
involvement in the pathogenesis of these tumors have not been
examined previously.
To determine the role of miR deregulation in the pathogenesis
of MCL, we have investigated the expression of a panel of miRs
located in commonly altered chromosomal regions in a series of
primary tumors and cell lines and their relationship to the
clinicopathologic characteristics of the patients.
Materials and Methods
Case selection and cell lines. Peripheral blood samples from 17 patients
with classic leukemic MCL and 50 nodal MCL, 36 classic and 14 blastoid
variants, were obtained from the Department of Pathology of the Hospital
Clı´nic and Hospital del Mar and Institute of Pathology of the University
of Wu¨rzburg. The leukemic cases were selected based on the sample
availability for tumor cell purification and the nodal cases based on the high
content of tumor cells (>85%). Tumor cells were purified in leukemic
samples as described previously (15). In addition, CD5+ and CD5 fractions
of normal B cells were obtained by cell sorting from equal cell amounts
from four tonsil samples using FACSVantageSE cell sorter (BD Biosciences)
of the Cytomic Unit Facility of Institut d’Investigacions Biome`diques August
Pi i Sunyer and with antibodies against CD19-FITC (Beckman Coulter) and
CD5-PE (BDBiosciences). Twelve reactive lymph nodeswere pooled and used
as an additional normal tissue sample for comparison with nodal MCL.
In two MCL patients, paired peripheral blood and tumor lymph node
samples were available and the CD19+CD5+ tumor cells were purified from
both. MCL-derived cell lines GRANTA519, REC1, JEKO1, UPN1, HBL2,
MINO, MAVER1, and JVM2 were also studied and grown as described
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previously (16). EBV infection status of these cell lines has been described
previously (17).
All MCL of the study were positive for cyclin D1 expression. Ki-67
proliferation antigen expression was studied by immunohistochemistry
on formalin-fixed, paraffin-embedded material of nodal MCL cases (18).
The gene expression profile of the leukemic MCL was examined previously
using Affymetrix U133 Plus 2.0 microarrays and tumor proliferation
signature was calculated according to Rosenwald and colleagues (19) as
the normalized mean expression of the 20 genes included in this signature.7
The immunoglobulin variable heavy chain genes (IgVH) mutational status
was studied as described previously (20). All patients gave informed consent
and the whole study was previously approved by the Hospital Clı´nic of
Barcelona Institutional Review Board.
miR selection. The complete list of the miRs analyzed is shown in
Supplementary Table S1. This set was selected to cover the highest number
of known miRs mapped at the most frequent chromosomal altered regions
in MCL (21, 22) but limited by the presence of homologous mature forms in
different genomic locations and the reagent availability (Applied Biosys-
tems). A total of 85 miRs were finally included corresponding to 3 located
at 11q13, 24 at 14q32, and 58 at loci involved in regions of chromosomal
gains/amplifications or losses in MCL (11). Additionally, miR-181a was also
included to explore its possible clinical relevance in MCL, because it had
been characterized in chronic lymphocytic leukemia (CLL) as the most
significant miR showing high levels associated with short time from
diagnosis to initial therapy (23). This miR was excluded for the correlation
analysis between the expression and genomic status because their two
variants map to two different chromosomal loci (see Supplementary Table S1)
and could not be differentiated in the expression analysis of the resulting
mature miR variants.
RNA isolation and reverse transcriptase–looped quantitative PCR.
Total RNA was isolated from all samples using Trizol reagent (Invitrogen).
The mRNA levels of the mature miRs previously selected were in-
vestigated by reverse transcriptase–looped quantitative PCR as described
previously (24). The CD5+/CD5 normal B-cell samples were used as
calibrators. As a normalization of RNA input, a noncoding RNA (RU19/
snoRA74A; Applied Biosystems) was selected by its location at 5q31.2, an
infrequently altered region in MCL, and their low variation amplification
values. miR quantifications in relative units were calculated with software
package SDS 2.1 (Applied Biosystems) based on 2DDCt method and
converted to log10 scale for more convenient data representation.
Reverse transcriptase–looped quantitative PCR of miR-17-5p and miR-
20a was done in 38 additional nodal MCL samples. MYC mRNA expression
in the 50 nodal MCL cases had been previously investigated by reverse
transcriptase–looped quantitative PCR (25).
Genomic analysis: single nucleotide polymorphism arrays. The
detection of DNA copy number changes and uniparental disomy was in-
vestigated in the cell lines and leukemic MCL using the GeneChip mapping
100K single nucleotide polymorphism array (Affymetrix) as described
previously (11). The genomic profile of 12 of these MCL cases has been
published previously (11), and 5 additional cases were investigated for the
present study using the same protocol and criteria. The genomic alterations
in the nonpurified nodal MCL samples had been previously analyzed using
comparative genomic hybridization (21). miR genomic loci status was
defined by their physical position on public databases overlapping with
chromosomal regions defined as altered in the studied samples.
Statistical and bioinformatics analysis. Nonsupervised clustering
analysis of miR expression data was done using an Euclidean-related
metrics (Manhattan distance) and a complete clustering algorithm (TIGR
MeV software package; ref. 26). The differential miR expression analysis
between MCL groups was done using unpaired/paired significance analysis
of microarrays (SAM) method as implemented in TIGR MeV software
package (26), adjusting delta parameter to ensure the lowest false discovery
rate (q < 0.01; refs. 27, 28). Differentially expressed miRs from MCL samples
compared with each of the considered controls were established using 95%
confidence interval of the difference of means between samples and
controls for each miR . In all comparisons, only miRs with detectable
expression in >50% of the samples in each group were considered.
The correlation between miR loci copy number changes and their
expression levels was analyzed using the Kendall s-b statistic. Genomic
alterations were divided into loss and gain/amplification. Only miR loci
with alterations present in >15% of the cases were included in the analysis.
Uniparental disomy was considered separately and analyzed using Kruskal-
Wallis test. For statistical correction of multiple comparisons, P values were
adjusted using the Benjamini and Hochberg false discovery rate method
(ref. 29; R package).8 Adjusted P values < 0.05 were considered significant.
Categorical data were compared using Fischer’s exact test, and Mann-Whitney
nonparametric test was used for comparisons of continuous variables.
The survival analysis was done using the Kaplan-Meier analysis, and
survival curves were compared with the log-rank test (SPSS software 13.0)
on the patients groups categorized by miR-17-5p/miR-20a and MYC ex-
pression levels. These groups were defined into high (above cutoff) or low
(at or below cutoff), and given that no clear criteria of gene overexpression
in tumors without increased gene dosage could be defined, expression
cutoff was set at the 70th percentile expression. This cutoff was the highest
to (a) maximize the number of patients in all the groups analyzed and (b)
define a high expression group including patients with gain/amplification of
these genes.
Results
miR expression profile in leukemic MCL. The expression of
the selected miRs was initially investigated in leukemic and cell line
MCL samples and compared with CD5+ and CD5 B-cell pools.
Leukemic MCL showed a miR expression profile different from
both B-cell controls (Fig. 1A ; Supplementary Table S2A-C), in-
cluding 17 and 9 miRs, respectively, which were not detectable in
these normal samples but were expressed in 12% to 100% of the
tumors (Supplementary Table S2A). Significant differences were
also detected in miRs with detectable expression in both B-cell
controls and tumors. Thus, 17 miRs showed a higher mean fold
change (MFC; 1.36-8.59), whereas 34 miRs were down-regulated in
the tumors compared with CD5+ B cells (MFC, 0.61-0.02; Fig. 1A ;
Supplementary Table S2B). Similarly, 2 miRs had significantly
higher levels in the tumors (MFC, 3.36-6.83), whereas 49 miRs were
significantly down-regulated (MFC, 0.59-0.01) in the tumors
compared with CD5 B cells (Fig. 1A ; Supplementary Table S2C).
The unsupervised hierarchical clustering analysis of the miR
expression in tumor samples and cell lines showed three distinctive
clusters corresponding to the cell lines and two groups of leukemic
MCL. These three clusters were observed using either normal CD5+
or CD5 B cells as reference calibrators (clusters A and B; Fig. 1A ;
Supplementary Fig. S1A).
To determine the significance of the two subgroups of MCL, we
studied several clinical and biological characteristics of these
tumors (Fig. 1A). Interestingly, the mutational status of the IgVH
genes was significantly different in the two clusters of MCL. Thus,
7 of 9 tumors in the cluster B had a hypermutated IgVH gene (<95%
homology), whereas 7 of 8 cases included in cluster A were
found unmutated (>98% homology; P = 0.012, Fischer’s exact test).
The number of genomic alterations detected by the single nucleo-
tide polymorphism array analysis was also significantly different be-
tween cluster A (mean, 6.5F 5.07) and cluster B (mean, 1.56F 2.35;
7 Ferna´ndez et al., unpublished data. 8 http://cran.r-project.org
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P = 0.024, Mann-Whitney test). In addition, the mean proliferation
signature obtained from the microarray expression analysis of these
tumors was also significantly higher in cluster A (mean, 0.17F 0.49)
than in cluster B (mean, 0.15 F 0.61; P = 0.043, Mann-Whitney
test; Supplementary Table S3). Although patients in cluster A
show a shorter median overall survival (15 months) than cluster B
patients (median overall survival not reached), the differences
were not significant.
Figure 1. Heat map of miR expression in MCL samples determined by quantitative PCR relative quantification (log relative units). Gray boxes, undetectable
expression. A, miR expression profile of purified tumor cells from peripheral blood in primary leukemic tumors, MCL cell lines, and two pools of normal tonsil CD5 and
CD5+CD19+ cells (calibrator). The nonsupervised hierarchical clustering separates the samples in three subgroups corresponding to the cell lines and two distinct
clusters of primary MCL (clusters A and B). The histologic variant, IgVH mutational status, survival, mean value of the proliferation signature, and number of
chromosomal alterations of each primary MCL are shown below the corresponding miR profile. B, miR expression profile of a nonpurified nodal MCL series and an
additional pool of reactive lymph nodes in reference to CD5+CD19+ cells (calibrator). The nonsupervised hierarchical clustering analysis showed two main clusters.
Additional data of these lymphomas are also shown below the corresponding miR profile. The proliferation index of the tumors was evaluated with Ki-67 immunostaining.
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To determine the miRs differentially expressed between these
two groups of MCL, we performed an unpaired SAM analysis.
A group of 28 miRs, all with high SAM statistical scores (>2),
showed a significant overexpression in cluster A compared with
cluster B (MFC, 4.12; range, 2.02-11.86; Table 1). An additional
supervised unpaired SAM analysis between IgVH mutational
classes was done. A total of 29 miRs showed a significant
overexpression in unmutated versus hypermutated IgVH MCL
cases (MFC, 3.41; range, 1.57-16.26; Supplementary Table S4) and
included 17 (61%) miRs of the differentially expressed miRs found
between MCL clusters A and B.
The third cluster in the unsupervised analysis corresponded to
the MCL cell lines. No significant differentially expressed miRs were
found between EBV+ (GRANTA519 and JVM2) and the remaining
EBV MCL cell lines. A SAM analysis comparing the expression
profile of the cell lines and primary tumors revealed 29 miRs
differentially expressed between these groups (Supplementary Table
S5). Only 4 miRs were not detectable in the cell lines but were
expressed in 12% to 65% of the tumors (Fig. 1A ; Supplementary
Table S2A).
miR expression profile in nodal MCL. The expression miR
profile was next examined in nodal MCL in reference also to CD5+/
CD5 B-cell pools. Nodal MCL samples showed a high number of
differentially expressed miRs (Supplementary Tables S5A and B).
Thus, 73 miRs were significantly overexpressed compared with CD5+
B cells (MFC, 3.18-1153.71). Similarly, 66 miRs were significantly over-
expressed (MFC, 1.92-2052.29), but only 3 miRs were down-regulated
(MFC, 0.29-0.12) in tumors compared with CD5 B cells. In addition,
the proportion of common deregulated miRs between nodal and
leukemic MCL samples (marked with asterisks in Supplementary
Tables S5A and B and S2B and C) was noticeable low in reference to
either CD5+ B cells (20.6% overexpressed and 29.4% down-regulated
miRs, respectively) or CD5 B cells (7.4% overexpressed and 9.8%
down-regulated miRs, respectively). Noticeably, miR-337 was detected
in the pool of reactive lymph nodes but was not expressed in the
CD5+/CD5 normal B cells or any tumor sample.
Unsupervised hierarchical clustering analysis of the relative miR
expression in the nodal tumors in reference to either normal CD5+/
CD5Bcells generated twomiR signatures that separate 4 and8 tumors
(Fig. 1B; Supplementary Fig. S1B) but were not related to significant
differences in histologic variants, Ki-67 proliferation index, IgVH
mutational status, or genomic complexity of the tumors (Fig. 1B).
miR expression and microenvironment of tumor cells. The
different pattern of miR expression in purified leukemic cells and
nodal lymphomas prompted us to evaluate the possible influence
of the nodal microenvironment on the miR expression profile. Thus,
we were able to study purified (>98%) MCL cells from matched
samples obtained simultaneously from leukemic and nodal samples
in two patients (identified as A-PB/A-Node and B-PB/B-Node
samples in Figs. 1A and 2). Most miRs were expressed at similar
levels in both samples in the two patients. However, 11 miRs had a
marked significant overexpression (3.6- to 21.9-fold change) in the
nodal sample compared with the leukemic cells of both cases, sug-
gesting that they may be modulated by influences of the tissue
microenvironment (Fig. 2).
miR expression and genetic alterations. The t(11;14)(q13;q32)
translocation is the primary genetic alteration in MCL (14). Several
miRs have been mapped in the chromosomal subregions involved,
including 7 miRs at 11q13 and 60 miRs at 14q32 (30). To determine
whether this translocation may deregulate them, we have com-
pared their expression in the cell lines and leukemic MCLwith those
Table 1. miR signature with significant differential expres-
sion between clusters A and B of leukemic MCL cases
miR Cytoband Score (d)* Fold change
miR-181a 1q31/9q33 2.93 11.86
miR-200c 12p13 2.92 11.40
miR-497 17p13 2.97 9.74
miR-22 17p13 2.70 5.35
miR-345 14q32 2.37 4.95
miR-485-5p 14q32 2.01 4.76
miR-190 15q22 2.46 4.73
miR-15b 3q26 3.46 4.66
miR-324-3p 17p13 2.48 4.41
miR-132 17p13 2.17 4.07
miR-342 14q32 2.77 3.60
miR-148b 12q13 3.32 3.58
miR-17-5p 13q31 2.10 3.14
let-7d 9q22 2.89 3.07
miR-452 Xq28 2.50 3.05
miR-30d 8q24 2.83 2.85
miR-17-3p 13q31 2.08 2.84
miR-192 11q13 2.07 2.81
miR-186 1p31 2.45 2.70
miR-28 3q28 3.18 2.68
miR-423 17q11 2.31 2.67
miR-20a 13q31 2.54 2.58
miR-30b 8q24 2.86 2.54
miR-197 1p13 2.30 2.47
miR-23b 9q23 2.54 2.45
miR-15a 13q14 2.02 2.20
miR-491 9p21 2.06 2.03
miR-32 9q31 2.09 2.02
*SAM statistical score.
Figure 2. Heat map representation of the significant miR expression differences
in paired samples of purified tumor cells from simultaneous matched
peripheral blood (PB) and tumor lymph nodes (NODE ) of two patients (A and B ).
Eleven miRs were found differentially expressed in the paired SAM analysis
of expression levels between the two tumor cell populations from these two
patients. Relative expression was obtained in reference to CD5+ control cells
but, additionally for each miR, its expression in the nodal samples has been
normalized in reference to the peripheral blood values for a more
clear representation.
Cancer Research
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in the normal CD5+/CD5 B cells. The analyzed miRs included
3 mapped at 11q13 (1 centromeric and 2 telomeric to the CCND1
gene) and 24 at 14q32 (all centromeric to the IgH gene; Sup-
plementary Fig. S2) covering several individual and polycistronic
miR regions (31). ThesemiRs had a highly variable expression among
the MCL samples (range, 0.16-2.24 relative units). The 3 11q13 miRs
showed significant higher levels in MCL samples compared with
CD5+ normal B cells but were down-regulated in reference to the
CD5 normal B cells irrespective of their location in the derivative
chromosomes and thus suggesting an absence of IgH enhancer
influence in their expression (Supplementary Fig. S2). The expres-
sion of most miRs located at 14q32 did not show significant
Figure 3. Correlation analysis of the miR locus copy number changes and expression levels in cell lines and leukemic MCL. A, representation of the correlation
Kendall s-b statistic results as a bar chart for each miR ordered by chromosomal physical position. Only miR loci with copy number alterations in >15% of cases were
included. A few miRs (crosses) showed a statistical significant correlation (P < 0.05). miRs at 13q31 showed a significant correlation after correction for multiple
comparison (asterisks ; adjusted P = 0.042). The percentage of cases with gains/amplifications (red ) and losses (green ) in leukemic MCL (PB-MCL) and cell lines is
represented as heat maps for each considered miR. B, heat map comparing the expression levels and gene copy number status for the miRs with a significant
correlation between these two parameters. For each miR , cell line and leukemic MCL results are mixed. The different cases are grouped by presence (red) or absence
(black ) of genomic alteration of the miR locus, and inside these categories, miR expression levels are shown ordered decreasingly from left to right.
MicroRNAs in Mantle Cell Lymphoma
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differences between tumor samples and both subsets of normal B
cells (Supplementary Fig. S2).
To determine the possible influence of DNA copy number
changes in the expression of the mature miRs , we performed a
correlation analysis between the miR expression levels in the cell
lines and leukemic MCL and the genomic data of the respective
chromosomal loci obtained in the single nucleotide polymorphism
array study. A significant positive correlation between increased
expression levels and high DNA copy number was found for the
miRs located at 8q24 (miR-30d), 11q13 (miR-139), 13q31 (miR-17-3p,
miR-17-5p, miR-18, miR-19a , and miR-20a), and 18q21 (miR-122a ;
Fig. 3; Supplementary Table S6). Interestingly, the relationship
between expression levels and copy number changes of the 13q31
miRs was observed even after stringent adjustment for multiple
testing (adjusted P = 0.042; Supplementary Table S6). The single
nucleotide polymorphism array analysis detected also regions of
partial uniparental disomy in all cell lines and 31% of the primary
MCL. These uniparental disomies contained the genomic loci of
24% and 7% of the examined miRs in the cell lines and primary
tumors, respectively. However, no significant association between
the genetic alteration and the expression levels was observed,
suggesting that the uniparental disomies do not deregulate the
expression of the studied miRs.
To confirm the influence of copy number changes on miR
expression in primary tumors, we expanded the study to the
12 nodal MCL in which a comparative genomic hybridization
analysis had been done previously. These cases included 8 tumors
with 13q31 genomic alterations (3 amplifications and 5 losses),
3 cases with 8q24 gains/amplifications, 2 tumors with gains of
11q13, and 1 case with 18q21 gain. A significant correlation was
observed between the 13q31 copy number changes and the
expression levels of the studied mature miRs of the miR-17-92
cluster (Fig. 4; Supplementary Table S7). No other significant
correlations were observed in this set of tumors.
MYC and 13q31 miR expression. Experimental studies have
shown that the miR-17-92 cluster may cooperate with MYC in the
development and progression of tumors (32). To determine whether
the overexpression of these genes could influence the outcome of
MCL patients, we analyzed the survival effect of the concomitant
overexpression of MYC and miR-17-5p and/or miR-20a miRs in
50 patients with nodal MCL. Concomitant high levels of MYC and
miR-17-5p or MYC and miR-20a were found in 8 patients who
noticeably had a significant shorter overall survival (median overall
survival, 17 months) than the 17 patients with high expression of
MYC or miR-17-5p/miR-20a alone (median overall survival, 48 months)
and the remaining 25 patients with low expression of all these genes
(median overall survival, 69 months; P = 0.025, log-rank test; Fig. 5).
The mean Ki-67 proliferation index in these three groups was
45.2 F 30, 38.9 F 23.7, and 29.8 F 15.6, respectively. Although the
proliferation tended to be higher in the tumors with higher levels of
MYC and miR-17-5p/miR-20a, the differences were not statistically
significant (P = 0.681, Kruskal-Wallis test).
Discussion
In this study, we have examined the expression profile of 86
selected miRs in a series of leukemic and nodal MCL. The com-
parison of leukemic MCL miR expression profiles with normal
CD5+/CD5 B cells showed that the tumors had a profile different
from both controls and included the up-regulation of several miRs
that were not detected in these normal counterparts. Interestingly,
the unsupervised hierarchical clustering analysis of highly purified
leukemic MCL cells revealed two distinctive subsets of tumors
showing significant differences in the IgVH mutational status,
proliferation signature, and number of chromosomal alterations.
Although the number of tumors in each group is limited, these
findings suggested that these clusters may correspond to two
subtypes of MCL with marked biological differences. Interestingly,
previous studies have recognized a subtype of MCL characterized
Figure 4. Box plot representing the relative expression
levels [relative units (RU )] of the examined miRs at 13q31
and their copy number changes in nodal MCL. All 5 miRs
showed a significant correlation between the expression
levels quantified by reverse transcriptase–looped
quantitative PCR and the gene dosage of this locus
according to comparative genomic hybridization results
[loss (LOSS ), wild-type (WT ), and amplification (AMP )].
Circles and asterisks, extreme values and outliers,
respectively.
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by a predominant leukemic presentation, higher number of IgVH
mutations, lower genetic complexity, and better outcome (33, 34).
The two clusters of MCL with different miR expression profile
identified in our study may correspond to this subtype and con-
ventional MCL, respectively.
This relationship between miR expression and different tumor
subsets may be reminiscent of the situation in CLL in which the
miR profile distinguishes two tumor subgroups related to the IgVH
mutational status (23, 35). miR-15a, miR-195, miR-23b, and miR-
142-3p, described previously as IgVH mutation-related miRs in CLL
(23, 36), were also included in the present study, but any of them
showed a significant difference expression related to the IgVH
mutation status in MCL. Interestingly, several up-regulated miRs in
the unmutated IgVH subset of MCL tumors have been involved in
tumor growth promotion, proliferation, and cell survival regulation.
Thus, the highest differentially expressedmiR in cluster A, miR-181a,
has been associated with more aggressive clinical behavior in CLL
andpromotes tumor growth ofmultiplemyeloma cells (23, 37, 38).miR-
181a also controls negatively the p53 activity by interfering with p300-
CBP-associated factor, an upstream regulator of p53 stability (37).
The causes of miR deregulation in tumors are not well known
but may include gene dosage alterations or rearrangements close
to miR loci (9, 39–41). In this study, we investigated a series of miRs
mapped to chromosomal regions frequently altered in MCL (14).
We found a significant correlation of the corresponding mature
miR levels with the gene dosage alterations for severalmiRs located
at 8q24 (miR-30d), 11q13 (miR-139), 13q31 (miR-17-3p, miR-17-5p,
miR-18, miR-19a , and miR-20a), and 18q21 (miR-122a). Interest-
ingly, this relationship for the mature miRs of the miR-17-92 cluster
was retained even after the stringent adjustment for multiple
testing. In a recent study, we showed that the precursor gene of this
cluster (c13orf25) was the only gene included in the minimal
common amplified region at 13q31 in MCL and its expression
levels were related to the gene copy number changes (11).
Overexpression of 13q31 miRs associated with gene amplification
has been also observed in Burkitt’s and diffuse large B-cell
lymphomas, indicating that it may be an important mechanism
in the pathogenesis of this group of aggressive lymphomas (42, 43).
The oncogenic role of the miR-17-92 cluster has been shown
previously and may involve several mechanisms including cooper-
ation with MYC inducing a decreasing in apoptosis (32, 44–46). On
the other hand,MYC overexpression has been recognized as a prog-
nostic factor in MCL (25). To determine the potential cooperation
of these two factors, we studied MYC and miR-17-5p/miR-20a
expression in 50 nodal MCL. Our results showed that tumors with
the concomitant highest levels of MYC and miR-17-5p/miR-20a had
significant shorter overall survival than cases with high expression of
only one or none of these factors. These results suggest that the
cooperation in tumor progression observed in experimental studies
may also occur in human MCL.
In this study, we observed marked differences in the expression
levels of several miRs between leukemic and nodal MCL. Although
nodal MCL were selected by high tumor content, these differences
may be due in part to contamination with other nonneoplastic cell
types. Nevertheless, miR-337 expression was not detected in any
leukemic MCL or nodal MCL in spite of being detected in the pool
of reactive nodal tissues, suggesting that the degree of cell contam-
ination of the nodal MCL was not enough to allow the detection of
this miR. To determine whether these differences could be due to
the different topographic location of the tumor, we were able to
purify tumor cells from simultaneous peripheral blood and lymph
node sample in two patients. Interestingly, we detected 11 miRs
that had a marked significant overexpression in the nodal sample
compared with the leukemic cells in both cases, suggesting that
they may be modulated by influences of the tissue microenviron-
ment. The idea that miR expression may be regulated in different
cell compartments is also supported by a recent study of miR
expression in CLL in which the expression of BIC/pri-miR-155 was
higher in cells of the proliferation growth centers, whereas miR-150
was mainly expressed by surrounding resting CLL cells (47).
Figure 5. Overall survival of 50 patients with nodal MCL
according to the combined expression of MYC and
miR-17-5p/miR-20a. MCL patients with concomitant high
expression of both MYC and miR-17-5p/miR-20a
(n = 8; line A ) have a significant shorter overall survival
than patients with high expression of only one (n = 17;
fail 5; line B) or none (n = 25; fail 10; line C ) of these
factors (P = 0.025, log-rank test).
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In summary, our results show that the miR expression profile in
MCL is deregulated in comparison with normal lymphoid cells and
distinguishes two subgroups of tumors that differ in the mutational
status of the IgVH genes, genomic complexity and proliferation.
The deregulation of some miRs is related to gene copy number
changes, whereas others seem to be modulated by microenviron-
ment influences. The concomitant high expression of MYC and
miR-17-5p/miR-20a from the miR-17-92 cluster seems to be
associated with tumors with a more aggressive behavior.
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